Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 2, 1996, Pages 285-293

  Verbist, L ^a   Verhaegen, J ^a   Wouters, Ch ^b   Vandenhoven, G ^b   Allemeersch, D ^c   Bardiau, C ^c   Bellon, A ^c   Carpentier, M ^c   Colaert, J ^c   Crokaert, F ^c   D'Hont, N ^c   De Brauw, W ^c   Deckers, P ^c   Declercq, Ph ^c   Dediste, A ^c   Delmee M ^c   De Mol, P ^c   De Muelenaere G ^c   De Puydt, H ^c   Desmarets, J M ^c   De Weer, M ^c   Dierick, J ^c   Fameree D ^c   Garrino, M G ^c   Glupczynski, I ^c   Goffinet, P ^c   Gonissen, V ^c   Goossens, H ^c   Hemmer, R ^c   Hubrechts, J M ^c   Leclercq, M ^c   Lievens, P ^c   Maes, P ^c   Magerman, K ^c   Marchal, J F ^c   Martens, F ^c   Melin, P ^c   Mertens, H J ^c   Mertens, A ^c   Meunier, F ^c   Pauquay, F ^c   Pepersack, F ^c   Potvliege, C ^c   Schneider, F ^c   Simon, G ^c   Simon, A ^c   Smekens, J ^c   Trigoux, J ^c   Ursi, J P ^c   Vael, C ^c   Vandelanoitte, P ^c   Van den Abeele, A M ^c   Vanden Bulcke, A ^c   Van de Vijvere, M ^c   Van Landuyt, H W ^c   Van Nimmen, L ^c   Van Noyen, R ^c   Vermaelen, K ^c   Vincke G ^c   Vuye, A ^c   Wautelet, M J ^c   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Cyanamid International   (Belgium)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; PSEUDOMONAS AERUGINOSA;

BACTERIA; BELGIUM; BETA-LACTAMASES; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALS; LUXEMBOURG; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; QUALITY CONTROL;

EID: 9244251951     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.2.285     Document Type: Article

References (17)

1. Appelbaum, P. C., Jacobs, M. R., Spangler, S. K. & Yamabe, S. (1986). Comparative activity of β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with β-lactams against β-lactamase-producing anaerobes. Antimicrobial Agents and Chemotherapy 30, 789-91.
2. Aronoff, S. C., Jacobs, M. R., Johenning, S. & Yamabe, S. (1984). Comparative activities of the β-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxycillin or ampicillin. Antimicrobial Agents and Chemotherapy 26, 580-2.
3. Bolmström, A., Arvidson, S., Ericsson, M. & Karlsson, A. (1989). RDM epsilometer, a new technique for antimicrobial susceptibility testing based on a predefined antibiotic gradient. In Abstracts of the Fourth European Congress of Clinical Microbiology, Nice, 1989. Abstract 1180, p. 495. European Society of Clinical Microbiology.
4. Brismar, B., Malmborg, A. S., Tunevall, G., Wretlind, B., Bergman, L., Mentzing, L. O. et al. (1992). Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrobial Agents and Chemotherapy 36, 2766-73.
5. Eklund, A.-E., Nord, C. E. and Swedish Study Group (1993). A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 79-85.
6. Fass, R. J. & Prior, R. B. (1989). Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrobial Agents and Chemotherapy 33, 1268-74.
7. Gorbach, S. L. (1993). Treatment of intra-abdominal infections. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 67-78.
8. Jacobs, M. R., Aronoff, S. C., Johenning, S., Shlaes, D. M. & Yamabe, S. (1986a). Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined β-lactamase-producing aerobic gram-negative bacilli. Antimicrobial Agents and Chemotherapy 29, 980-5.
9. Jacobs, M. R., Aronoff, S. C , Johenning, S. & Yamabe, S. (1986b). Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads. Journal of Antimicrobial Chemotherapy 18, 177-84.
10. Kuck, N. A., Jacobus, N. V., Petersen, P. J., Weiss, W. J. & Testa, R. T. (1989). Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrobial Agents and Chemotherapy 33, 1964-9.
11. Livermore, D. M. (1993). Determinants of the activity β-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 9-21.
12. Moosdeen, F., Williams, J. D. & Yamabe, S. (1988). Antibacterial characteristics of YTR 830, a sulfone β-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrobial Agents and Chemotherapy 32, 925-7.
13. Mouton, Y., Leroy, O., Beuscart, C., Chidiac, C., Senneville, E., Ajana, F. et al. (1993). Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 87-96.
14. National Committee for Clinical Laboratory Standards. (1994). Performance Standards for Antimicrobial Susceptibility Testing: M100-S5. NCCLS, Villanova, PA.
15. Tan, J. S., Wishnow, R. M., Talan, D. A., Duncanson, F. P., Norden, C. W. & the Piperacillin/Tazobactam Skin and Skin Structure Study Group (1993). Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin/tazobactam versus ticarcillin-clavulanate. Antimicrobial Agents and Chemotherapy 37, 1580-6.
16. Tassler, H., Cullmann, W. & Elhardt, D. (1993). Therapy of soft tissue infections with piperacillin tazobactam. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 105-12.
17. Wise, R. (1993). The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 97-104.